Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.46 |
| ▸ | TCF4 | P15884 | 2/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127728 | 0.84 | HDAC2 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2150848 | 0.82 | WDR5 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2196090 | 0.82 | F2 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3133160 | 0.81 | CA1 (0.46) | CA1CA2CA12CA9KDR | |
| SCHEMBL3125672 | 0.81 | CA1 (0.43) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL3136938 | 0.81 | CA1 (0.43) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL8368843 | 0.81 | MEN1 (0.55) | POLBMEN1KMT2AKDM1AMAOA | |
| SCHEMBL942893 | 0.80 | IDO1 (0.51) | MEN1KMT2A | |
| SCHEMBL13323820 | 0.80 | CA1 (0.43) | CA1CA2POLBMEN1KMT2A | |
| SCHEMBL15946029 | 0.79 | HDAC2 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8674137-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113539-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | HDAC3 693/4885HDAC4 542/4885HDAC1 1685/4885 |
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | HDAC3 693/4885HDAC4 542/4885HDAC1 1685/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | HDAC3 693/4885HDAC4 542/4885HDAC1 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.